{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T10:49:48Z","timestamp":1795085388051,"version":"4.10.2"},"reference-count":109,"publisher":"Bentham Science Publishers Ltd.","issue":"13","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDT"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:sec><jats:title>Abstract:<\/jats:title><jats:p>Covid-19 may be associated with various neurological disorders, including dysautono-mia, a dysfunction of the autonomic nervous system (ANS). In Covid-19, hypoxia, immuno-inflammatory abnormality, and deregulation of the renin-angiotensin system (RAS) may increase sympathetic discharge with dysautonomia development. Direct SARS-CoV-2 cytopathic effects and associated inflammatory reaction may lead to neuroinflammation, affecting different parts of the central nervous system (CNS), including the autonomic center in the hypothalamus, causing dysau-tonomia. High circulating AngII, hypoxia, oxidative stress, high pro-inflammatory cytokines, and emotional stress can also provoke autonomic deregulation and high sympathetic outflow with the development of the sympathetic storm. During SARS-CoV-2 infection with neuro-invasion, GABA-ergic neurons and nicotinic acetylcholine receptor (nAChR) are inhibited in the hypothalam-ic pre-sympathetic neurons leading to sympathetic storm and dysautonomia. Different therapeutic modalities are applied to treat SARS-CoV-2 infection, like antiviral and anti-inflammatory drugs. Ivermectin (IVM) is a robust repurposed drug widely used to prevent and manage mild-moderate Covid-19. IVM activates both GABA-ergic neurons and nAChRs to mitigate SARS-CoV-2 infec-tion-induced dysautonomia. Therefore, in this brief report, we try to identify the potential role of IVM in managing Covid-19-induced dysautonomia.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1389450123666220810102406","type":"journal-article","created":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T06:24:24Z","timestamp":1660199064000},"page":"1277-1287","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Central Effects of Ivermectin in Alleviation of Covid-19-induced Dysauto-nomia"],"prefix":"10.2174","volume":"23","author":[{"given":"Athanasios","family":"Alexiou","sequence":"first","affiliation":[{"name":"Department of Science and Engineering, Novel Global Community Educational Foundation, Hebersham, Australia"},{"name":"AFNP Med, Wien, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaber El-Saber","family":"Batiha","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Therapeutics, Faculty of Veterinary Medicine, Damanhour University, Damanhour 22511, AlBeheira, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayder M.","family":"Al-kuraishy","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Medicine, College of Medicine, AL-Mustansiriyiah University, Baghdad, Iraq"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali I.","family":"Al-Gareeb","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Medicine, College of Medicine, AL-Mustansiriyiah University, Baghdad, Iraq"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"644295","DOI":"10.3389\/fmed.2021.644295","volume":"8","author":"Al-Kuraishy H.M.","year":"2021","unstructured":"Al-Kuraishy H.M.; Al-Gareeb A.I.; Alblihed M.; Cruz-Martins N.; Batiha G.E.; COVID-19 and risk of acute ischemic stroke and acute lung injury in patients with type ii diabetes mellitus: The anti-inflammatory role of metformin. Front Med (Lausanne) 2021,8,644295","journal-title":"Front Med (Lausanne)"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"4161","DOI":"10.1007\/s11010-021-04232-z","volume":"476","author":"Al-Kuraishy H.M.","year":"2021","unstructured":"Al-Kuraishy H.M.; Al-Gareeb A.I.; Alzahrani K.J.; Cruz-Martins N.; Batiha G.E.; The potential role of neopterin in Covid-19: A new perspective. Mol Cell Biochem 2021,476(11),4161-4166","journal-title":"Mol Cell Biochem"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"102008","DOI":"10.1016\/j.pupt.2021.102008","volume":"67","author":"Al-Kuraishy H.M.","year":"2021","unstructured":"Al-Kuraishy H.M.; Al-Gareeb A.I.; Qusty N.; Cruz-Martins N.; El-Saber Batiha G.; Sequential doxycycline and colchicine combination therapy in Covid-19: The salutary effects. Pulm Pharmacol Ther 2021,67,102008","journal-title":"Pulm Pharmacol Ther"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"114431","DOI":"10.1016\/j.bcp.2021.114431","volume":"185","author":"Lugnier C.","year":"2021","unstructured":"Lugnier C.; Al-Kuraishy H.M.; Rousseau E.; PDE4 inhibition as a therapeutic strategy for improvement of pulmonary dysfunctions in Covid-19 and cigarette smoking. Biochem Pharmacol 2021,185,114431-114438","journal-title":"Biochem Pharmacol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"174196","DOI":"10.1016\/j.ejphar.2021.174196","volume":"904","author":"Al-Kuraishy H.M.","year":"2021","unstructured":"Al-Kuraishy H.M.; Al-Gareeb A.I.; Almulaiky Y.Q.; Cruz-Martins N.; El-Saber Batiha G.; Role of leukotriene pathway and montelukast in pulmonary and extrapulmonary manifestations of Covid-19: The enigmatic entity. Eur J Pharmacol 2021,904,174196","journal-title":"Eur J Pharmacol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"141","DOI":"10.4103\/JMAU.JMAU_63_20","volume":"8","author":"Al-Kuraishy H.M.","year":"2020","unstructured":"Al-Kuraishy H.M.; Al-Gareeb A.I.; Al-Niemi M.S.; Al-Buhadily A.K.; Al-Harchan N.A.; Lugnier C.; COVID-19 and phosphodiesterase enzyme type 5 inhibitors. J Microsc Ultrastruct 2020,8(4),141-145","journal-title":"J Microsc Ultrastruct"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"6395","DOI":"10.4081\/pr.2016.6395","volume":"8","author":"Poddighe D.","year":"2016","unstructured":"Poddighe D.; Marseglia G.L.; Is there any relationship between extra-pulmonary manifestations of Mycoplasma pneumoniae infection and atopy\/respiratory allergy in children? Pediatr Rep 2016,8(1),6395","journal-title":"Pediatr Rep"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"bcr2015214044","DOI":"10.1136\/bcr-2015-214044","volume":"2016","author":"Dhaliwal K.","year":"2016","unstructured":"Dhaliwal K.; Enright K.; Rare extrapulmonary complications of Mycoplasma pneumoniae infection. BMJ Case Rep 2016,2016,bcr2015214044","journal-title":"BMJ Case Rep"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/irv.12470","volume":"11","author":"Sellers S.A.","year":"2017","unstructured":"Sellers S.A.; Hagan R.S.; Hayden F.G.; Fischer W.A.; The hidden burden of influenza: A review of the extra-pulmonary complications of influenza infection. Influenza Other Respir Viruses 2017,11(5),372-393","journal-title":"Influenza Other Respir Viruses"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"624968","DOI":"10.3389\/fneur.2021.624968","volume":"12","author":"Goodman B.P.","year":"2021","unstructured":"Goodman B.P.; Khoury J.A.; Blair J.E.; Grill M.F.; COVID-19 dysautonomia. Front Neurol 2021,12,624968","journal-title":"Front Neurol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1089\/neu.2008.0536","volume":"38","author":"Dolce G.","year":"2021","unstructured":"Dolce G.; Quintieri M.; Leto E.; Dysautonomia and clinical outcome in vegetative state. J Neurotrauma 2021,38(10),1441-1444","journal-title":"J Neurotrauma"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1111\/head.13659","volume":"59","author":"Wig R.","year":"2019","unstructured":"Wig R.; Oakley C.B.; Dysautonomia and headache in the pediatric population. Headache 2019,59(9),1582-1588","journal-title":"Headache"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"e63","DOI":"10.7861\/clinmed.2020-0896","volume":"21","author":"Dani M.","year":"2021","unstructured":"Dani M.; Dirksen A.; Taraborrelli P.; Autonomic dysfunction in \u2018long COVID\u2019: Rationale, physiology and management strategies. Clin Med (Lond) 2021,21(1),e63-e67","journal-title":"Clin Med (Lond)"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1007\/s10067-018-4300-2","volume":"37","author":"Mart\u00ednez-Lav\u00edn M.","year":"2018","unstructured":"Mart\u00ednez-Lav\u00edn M.; Fibromyalgia and small fiber neuropathy: The plot thickens! Clin Rheumatol 2018,37(12),3167-3171","journal-title":"Clin Rheumatol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1007\/s12026-014-8575-3","volume":"60","author":"Poddighe D.","year":"2014","unstructured":"Poddighe D.; Castelli L.; Marseglia G.L.; Bruni P.; A sudden onset of a pseudo-neurological syndrome after HPV-16\/18 AS04-adjuvated vaccine: Might it be an Autoimmune\/inflammatory Syndrome by Adjuvants (ASIA) presenting as a somatoform disorder? Immunol Res 2014,60(2-3),236-246","journal-title":"Immunol Res"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"14042","DOI":"10.1038\/s41598-021-93546-5","volume":"11","author":"Barizien N.","year":"2021","unstructured":"Barizien N.; Le Guen M.; Russel S.; Touche P.; Huang F.; Vall\u00e9e A.; Clinical characterization of dysautonomia in long COVID-19 patients. Sci Rep 2021,11(1),14042","journal-title":"Sci Rep"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1113\/JP278864","volume":"598","author":"D\u00edaz H.S.","year":"2020","unstructured":"D\u00edaz H.S.; Toledo C.; Andrade D.C.; Marcus N.J.; Del Rio R.; Neuroinflammation in heart failure: New insights for an old disease. J Physiol 2020,598(1),33-59","journal-title":"J Physiol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"3681","DOI":"10.1111\/febs.15481","volume":"287","author":"Porzionato A.","year":"2020","unstructured":"Porzionato A.; Emmi A.; Barbon S.; Sympathetic activation: A potential link between comorbidities and COVID-19. FEBS J 2020,287(17),3681-3688","journal-title":"FEBS J"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s15010-020-01509-1","volume":"49","author":"Wolff D.","year":"2021","unstructured":"Wolff D.; Nee S.; Hickey N.S.; Marschollek M.; Risk factors for Covid-19 severity and fatality: A structured literature review. Infection 2021,49(1),15-28","journal-title":"Infection"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.jaccas.2021.01.009","volume":"3","author":"Johansson M.","year":"2021","unstructured":"Johansson M.; St\u00e5hlberg M.; Runold M.; Long-haul post-COVID-19 symptoms presenting as a variant of postural orthostatic tachycardia syndrome: The Swedish experience. JACC Case Rep 2021,3(4),573-580","journal-title":"JACC Case Rep"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s10286-021-00803-8","volume":"31","author":"Shouman K.","year":"2021","unstructured":"Shouman K.; Vanichkachorn G.; Cheshire W.P.; Autonomic dysfunction following COVID-19 infection: An early experience. Clin Auton Res 2021,31(3),385-394","journal-title":"Clin Auton Res"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.7860\/JCDR\/2021\/46795.14529","volume":"15","author":"Shoumann W.M.","year":"2021","unstructured":"Shoumann W.M.; Hegazy A.A.; Nafae R.M.; Use of ivermectin as a potential chemoprophylaxis for COVID-19 in Egypt: A randomized clinical trial. J Clin Diagn Res 2021,15(2),2021","journal-title":"J Clin Diagn Res"},{"key":"ref=23","first-page":"317","volume":"8","author":"Juarez M.","year":"2018","unstructured":"Juarez M.; Schcolnik-Cabrera A.; Due\u00f1as-Gonzalez A.; The multitargeted drug ivermectin: From an antiparasitic agent to a repositioned cancer drug. Am J Cancer Res 2018,8(2),317-331","journal-title":"Am J Cancer Res"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1177\/009127002401382731","volume":"42","author":"Guzzo C.A.","year":"2002","unstructured":"Guzzo C.A.; Furtek C.I.; Porras A.G.; Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects. J Clin Pharmacol 2002,42(10),1122-1133","journal-title":"J Clin Pharmacol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.14202\/vetworld.2019.1204-1211","volume":"12","author":"Sharun K.","year":"2019","unstructured":"Sharun K.; Shyamkumar T.S.; Aneesha V.A.; Dhama K.; Pawde A.M.; Pal A.; Current therapeutic applications and pharmacokinetic modulations of ivermectin. Vet World 2019,12(8),1204-1211","journal-title":"Vet World"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1242\/jeb.118570","volume":"218","author":"Meyers J.I.","year":"2015","unstructured":"Meyers J.I.; Gray M.; Kuklinski W.; Characterization of the target of ivermectin, the glutamate-gated chloride channel, from Anopheles gambiae. J Exp Biol 2015,218(Pt 10),1478-1486","journal-title":"J Exp Biol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"e1883","DOI":"10.1371\/journal.pntd.0001883","volume":"6","author":"M\u00e9nez C.","year":"2012","unstructured":"M\u00e9nez C.; Sutra J.F.; Prichard R.; Lespine A.; Relative neurotoxicity of ivermectin and moxidectin in Mdr1ab (-\/-) mice and effects on mammalian GABA(A) channel activity. PLoS Negl Trop Dis 2012,6(11),e1883","journal-title":"PLoS Negl Trop Dis"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1007\/s00204-021-03025-z","volume":"95","author":"Rendic S.P.","year":"2021","unstructured":"Rendic S.P.; Metabolism and interactions of ivermectin with human cytochrome P450 enzymes and drug transporters, possible adverse and toxic effects. Arch Toxicol 2021,95(5),1535-1546","journal-title":"Arch Toxicol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1113\/JP275236","volume":"596","author":"Chen I.S.","year":"2018","unstructured":"Chen I.S.; Kubo Y.; Ivermectin and its target molecules: Shared and unique modulation mechanisms of ion channels and receptors by ivermectin. J Physiol 2018,596(10),1833-1845","journal-title":"J Physiol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1038\/ncomms2924","volume":"4","author":"Jin L.","year":"2013","unstructured":"Jin L.; Feng X.; Rong H.; The antiparasitic drug ivermectin is a novel FXR ligand that regulates metabolism. Nat Commun 2013,4(1),1937","journal-title":"Nat Commun"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1002\/jat.3074","volume":"35","author":"Kauthale R.R.","year":"2015","unstructured":"Kauthale R.R.; Dadarkar S.S.; Husain R.; Karande V.V.; Gatne M.M.; Assessment of temperature-induced hERG channel blockade variation by drugs. J Appl Toxicol 2015,35(7),799-05","journal-title":"J Appl Toxicol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"5895","DOI":"10.1113\/JP274871","volume":"595","author":"Chen I.S.","year":"2017","unstructured":"Chen I.S.; Tateyama M.; Fukata Y.; Uesugi M.; Kubo Y.; Ivermectin activates GIRK channels in a PIP2 -dependent, G\u03b2\u03b3 -independent manner and an amino acid residue at the slide helix governs the activation. J Physiol 2017,595(17),5895-5912","journal-title":"J Physiol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1208\/s12248-007-9000-9","volume":"10","author":"Gonz\u00e1lez Canga A.","year":"2008","unstructured":"Gonz\u00e1lez Canga A.; Sahag\u00fan Prieto A.M.; Diez Li\u00e9bana M.J.; Fern\u00e1ndez Mart\u00ednez N.; Sierra Vega M.; Garc\u00eda Vieitez J.J.; The pharmacokinetics and interactions of ivermectin in humans-A mini-review. AAPS J 2008,10(1),42-46","journal-title":"AAPS J"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"D237","DOI":"10.1093\/nar\/gkp970","volume":"38","author":"Preissner S.","year":"2010","unstructured":"Preissner S.; Kroll K.; Dunkel M.; SuperCYP: A comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res 2010,38(Database issue),D237-D243","journal-title":"Nucleic Acids Res"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1172\/JCI118214","volume":"96","author":"Schinkel A.H.","year":"1995","unstructured":"Schinkel A.H.; Wagenaar E.; van Deemter L.; Mol C.A.; Borst P.; Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 1995,96(4),1698-1705","journal-title":"J Clin Invest"},{"key":"ref=36","first-page":"1165","volume":"47","author":"Dowling P.","year":"2006","unstructured":"Dowling P.; Pharmacogenetics: It\u2019s not just about ivermectin in collies. Can Vet J 2006,47(12),1165-1168","journal-title":"Can Vet J"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1002\/jps.22262","volume":"100","author":"Jani M.","year":"2011","unstructured":"Jani M.; Makai I.; Kis E.; Ivermectin interacts with human ABCG2. J Pharm Sci 2011,100(1),94-97","journal-title":"J Pharm Sci"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s002280050131","volume":"50","author":"Baraka O.Z.","year":"1996","unstructured":"Baraka O.Z.; Mahmoud B.M.; Marschke C.K.; Geary T.G.; Homeida M.M.; Williams J.F.; Ivermectin distribution in the plasma and tissues of patients infected with Onchocerca volvulus. Eur J Clin Pharmacol 1996,50(5),407-410","journal-title":"Eur J Clin Pharmacol"},{"key":"ref=39","unstructured":"Stromectrol. FDA approved Package insert 2009. Merck"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1080\/004982598239597","volume":"28","author":"Zeng Z.","year":"1998","unstructured":"Zeng Z.; Andrew N.W.; Arison B.H.; Luffer-Atlas D.; Wang R.W.; Identification of cytochrome P4503A4 as the major enzyme responsible for the metabolism of ivermectin by human liver microsomes. Xenobiotica 1998,28(3),313-321","journal-title":"Xenobiotica"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"e00712","DOI":"10.1002\/prp2.712","volume":"9","author":"Tipthara P.","year":"2021","unstructured":"Tipthara P.; Kobylinski K.C.; Godejohann M.; Identification of the metabolites of ivermectin in humans. Pharmacol Res Perspect 2021,9(1),e00712","journal-title":"Pharmacol Res Perspect"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"e0006934","DOI":"10.1371\/journal.pntd.0006934","volume":"12","author":"Xu T.L.","year":"2018","unstructured":"Xu T.L.; Han Y.; Liu W.; Antivirus effectiveness of ivermectin on dengue virus type 2 in Aedes albopictus. PLoS Negl Trop Dis 2018,12(11),e0006934","journal-title":"PLoS Negl Trop Dis"},{"key":"ref=43","first-page":"127","volume":"2","author":"Nguyen C.","year":"2015","unstructured":"Nguyen C.; Burton T.; Kuklinski W.; Gray M.; Foy B.D.; Ivermectin for the control of west nile virus transmission. New Horiz Transl Med 2015,2(4-5),127","journal-title":"New Horiz Transl Med"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.bbrc.2020.10.042","volume":"538","author":"Jans D.A.","year":"2021","unstructured":"Jans D.A.; Wagstaff K.M.; The broad spectrum host-directed agent ivermectin as an antiviral for SARS-CoV-2? Biochem Biophys Res Commun 2021,538,163-172","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3390\/scipharm88030036","volume":"88","author":"Mudatsir M.","year":"2020","unstructured":"Mudatsir M.; Yufika A.; Nainu F.; Antiviral activity of ivermectin against SARS-CoV-2: An old-fashioned dog with a new trick\u2014A literature review. Sci Pharm 2020,88(3),36","journal-title":"Sci Pharm"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"e00710","DOI":"10.1128\/JVI.00710-20","volume":"94","author":"King C.R.","year":"2020","unstructured":"King C.R.; Tessier T.M.; Dodge M.J.; Weinberg J.B.; Mymryk J.S.; Inhibition of human adenovirus replication by the importin \u03b1\/\u03b21 nuclear import inhibitor ivermectin. J Virol 2020,94(18),e00710-e00720","journal-title":"J Virol"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.antiviral.2012.06.008","volume":"95","author":"Caly L.","year":"2012","unstructured":"Caly L.; Wagstaff K.M.; Jans D.A.; Nuclear trafficking of proteins from RNA viruses: Potential target for antivirals? Antiviral Res 2012,95(3),202-206","journal-title":"Antiviral Res"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.3390\/cells9092100","volume":"9","author":"Jans D.A.","year":"2020","unstructured":"Jans D.A.; Wagstaff K.M.; Ivermectin as a broad-spectrum host-directed antiviral: The real deal? Cells 2020,9(9),2100","journal-title":"Cells"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"3636557","DOI":"10.2139\/ssrn.3636557","author":"Scheim D.","year":"2020","unstructured":"Scheim D.; Ivermectin for COVID-19 treatment: Clinical response at quasi-threshold doses via hypothesized alleviation of CD147-mediated vascular occlusion. SSRN 2020,3636557-24","journal-title":"SSRN"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1007\/s00210-020-01902-5","volume":"393","author":"Rizzo E.","year":"2020","unstructured":"Rizzo E.; Ivermectin, antiviral properties and COVID-19: A possible new mechanism of action. Naunyn Schmiedebergs Arch Pharmacol 2020,393(7),1153-1156","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s00011-011-0307-8","volume":"60","author":"Yan S.","year":"2011","unstructured":"Yan S.; Ci X.; Chen N.; Anti-inflammatory effects of ivermectin in mouse model of allergic asthma. Inflamm Res 2011,60(6),589-596","journal-title":"Inflamm Res"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s13555-017-0176-3","volume":"7","author":"De M\u00e9nonville S.T.","year":"2017","unstructured":"De M\u00e9nonville S.T.; Rosignoli C.; Soares E.; Topical treatment of rosacea with ivermectin inhibits gene expression of cathelicidin innate immune mediators, LL-37 and KLK5, in reconstructed and ex vivo skin models. Dermatol Ther (Heidelb) 2017,7(2),213-225","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"e21272","DOI":"10.7759\/cureus.21272","volume":"14","author":"Kerr L.","year":"2022","unstructured":"Kerr L.; Cadegiani F.A.; Baldi F.; Ivermectin prophylaxis used for COVID-19: A citywide, prospective, observational study of 223,128 subjects using propensity score matching. Cureus 2022,14(1),e21272","journal-title":"Cureus"},{"key":"ref=54","doi-asserted-by":"crossref","first-page":"101","DOI":"10.4103\/bbrj.bbrj_109_20","volume":"4","author":"Al-Kuraishy H.M.","year":"2020","unstructured":"Al-Kuraishy H.M.; Hussien N.R.; Al-Naimi M.S.; Al-Buhadily A.K.; Al-Gareeb A.I.; Lungnier C.; Is Ivermectin-Azithromycin combination the next step for COVID-19? Biomed Biotechnol Res J 2020,4(5),101","journal-title":"Biomed Biotechnol Res J"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s10286-017-0452-4","volume":"28","author":"Carod-Artal F.J.","year":"2018","unstructured":"Carod-Artal F.J.; Infectious diseases causing autonomic dysfunction. Clin Auton Res 2018,28(1),67-81","journal-title":"Clin Auton Res"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.autrev.2012.04.004","volume":"12","author":"Sternberg Z.","year":"2012","unstructured":"Sternberg Z.; Autonomic dysfunction: A unifying multiple sclerosis theory, linking chronic cerebrospinal venous insufficiency, vitamin D (3), and epstein-barr virus. Autoimmun Rev 2012,12(2),250-259","journal-title":"Autoimmun Rev"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s11940-020-00647-z","volume":"22","author":"Lima M.","year":"2020","unstructured":"Lima M.; Siokas V.; Aloizou A.M.; Unraveling the possible routes of SARS-COV-2 invasion into the central nervous system. Curr Treat Options Neurol 2020,22(11),37","journal-title":"Curr Treat Options Neurol"},{"key":"ref=58","first-page":"S133","volume":"71","author":"Hussien N.R.","year":"2021","unstructured":"Hussien N.R.; Al-Niemi M.S.; Al-Kuraishy H.M.; Al-Gareeb A.I.; Statins and Covid-19: The neglected front of bidirectional effects. J Pak Med Assoc 2021,71(12)(Suppl. 8),S133-S136","journal-title":"J Pak Med Assoc"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"e07311","DOI":"10.1016\/j.heliyon.2021.e07311","volume":"7","author":"Rahbar A.","year":"2021","unstructured":"Rahbar A.; Shakyba S.; Ghaderi M.; Ivermectin-functionalized multiwall carbon nanotube enhanced the locomotor activity and neuropathic pain by modulating M1\/M2 macrophage and decrease oxidative stress in rat model of spinal cord injury. Heliyon 2021,7(6),e07311","journal-title":"Heliyon"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"e01084","DOI":"10.1016\/j.sciaf.2021.e01084","volume":"18","author":"Batiha G.E.","year":"2021","unstructured":"Batiha G.E.; Al-Gareeb D.A.I.; Qusti S.; Common NLRP3 inflammasome inhibitors and Covid-19: Divide and conquer. Sci Am 2021,18,e01084","journal-title":"Sci Am"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"644095","DOI":"10.3389\/fcvm.2021.644095","volume":"8","author":"Al-Kuraishy H.M.","year":"2021","unstructured":"Al-Kuraishy H.M.; Al-Gareeb A.I.; Alblihed M.; Guerreiro S.G.; Cruz-Martins N.; Batiha G.E.; COVID-19 in relation to hyperglycemia and diabetes mellitus. Front Cardiovasc Med 2021,8,644095","journal-title":"Front Cardiovasc Med"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1002\/jmv.26521","volume":"93","author":"Dey J.","year":"2021","unstructured":"Dey J.; Alam M.T.; Chandra S.; Neuroinvasion of SARS-CoV-2 may play a role in the breakdown of the respiratory center of the brain. J Med Virol 2021,93(3),1296-1303","journal-title":"J Med Virol"},{"key":"ref=63","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.21873\/invivo.12134","volume":"34","author":"Lehrer S.","year":"2020","unstructured":"Lehrer S.; Rheinstein P.H.; Ivermectin docks to the SARS-CoV-2 spike receptor-binding domain attached to ACE2. In Vivo 2020,34(5),3023-3026","journal-title":"In Vivo"},{"key":"ref=64","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1096\/fj.201500187RR","volume":"30","author":"Franco M.","year":"2016","unstructured":"Franco M.; Bautista-P\u00e9rez R.; Cano A.; Pacheco U.; P\u00e9rez-Mendez O.; ATP and activation Of P2X1 And P2X7 renal receptors. A new concept in the pathophysiology of renal vasoconstriction in angiotensin II-induced hypertension. FASEB J 2016,30,739-2","journal-title":"FASEB J"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1152\/physrev.00035.2020","volume":"101","author":"Sriram K.","year":"2021","unstructured":"Sriram K.; Insel P.A.; Inflammation and thrombosis in COVID-19 pathophysiology: Proteinase-activated and purinergic receptors as drivers and candidate therapeutic targets. Physiol Rev 2021,101(2),545-567","journal-title":"Physiol Rev"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1124\/jpet.110.167908","volume":"334","author":"Asatryan L.","year":"2010","unstructured":"Asatryan L.; Popova M.; Perkins D.; Trudell J.R.; Alkana R.L.; Davies D.L.; Ivermectin antagonizes ethanol inhibition in purinergic P2X4 receptors. J Pharmacol Exp Ther 2010,334(3),720-728","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1038\/nm.4173","volume":"22","author":"Pijacka W.","year":"2016","unstructured":"Pijacka W.; Moraes D.J.; Ratcliffe L.E.; Purinergic receptors in the carotid body as a new drug target for controlling hypertension. Nat Med 2016,22(10),1151-1159","journal-title":"Nat Med"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"102741","DOI":"10.1016\/j.autneu.2020.102741","volume":"230","author":"Minic Z.","year":"2021","unstructured":"Minic Z.; O\u2019Leary D.S.; Reynolds C.A.; Purinergic receptor antagonism: A viable strategy for the management of autonomic dysreflexia? Auton Neurosci 2021,230,102741","journal-title":"Auton Neurosci"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"649128","DOI":"10.3389\/fnut.2021.649128","volume":"8","author":"Al-Kuraishy H.M.","year":"2021","unstructured":"Al-Kuraishy H.M.; Al-Gareeb A.I.; Faidah H.; Al-Maiahy T.J.; Cruz-Martins N.; Batiha G.E.; The looming effects of estrogen in Covid-19: A rocky rollout. Front Nutr 2021,8,649128","journal-title":"Front Nutr"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"749291","DOI":"10.3389\/fimmu.2021.749291","volume":"12","author":"Al-Kuraishy H.M.","year":"2021","unstructured":"Al-Kuraishy H.M.; Al-Gareeb A.I.; Mostafa-Hedeab G.; Effects of \u03b2-blockers on the sympathetic and cytokines storms in Covid-19. Front Immunol 2021,12,749291","journal-title":"Front Immunol"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/978-1-4939-1568-2_9","author":"Forsythe P.","year":"2015","unstructured":"Forsythe P.; The parasympathetic nervous system as a regulator of mast cell function. Mast Cells 2015,141-154","journal-title":"Mast Cells"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.toxrep.2020.12.013","volume":"8","author":"Alexandris N.","year":"2020","unstructured":"Alexandris N.; Lagoumintzis G.; Chasapis C.T.; Nicotinic cholinergic system and COVID-19: In silico evaluation of nicotinic acetylcholine receptor agonists as potential therapeutic interventions. Toxicol Rep 2020,8,73-83","journal-title":"Toxicol Rep"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"110331","DOI":"10.1016\/j.mehy.2020.110331","volume":"145","author":"Ahmad F.","year":"2020","unstructured":"Ahmad F.; COVID-19 induced ARDS, and the use of galantamine to activate the cholinergic anti-inflammatory pathway. Med Hypotheses 2020,145,110331","journal-title":"Med Hypotheses"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1124\/mol.53.2.283","volume":"53","author":"Krause R.M.","year":"1998","unstructured":"Krause R.M.; Buisson B.; Bertrand S.; Ivermectin: A positive allosteric effector of the \u03b17 neuronal nicotinic acetylcholine receptor. Mol Pharmacol 1998,53(2),283-294","journal-title":"Mol Pharmacol"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.nbd.2004.02.009","volume":"16","author":"Zbarsky V.","year":"2004","unstructured":"Zbarsky V.; Thomas J.; Greenfield S.; Bioactivity of a peptide derived from acetylcholinesterase: Involvement of an ivermectin-sensitive site on the alpha 7 nicotinic receptor. Neurobiol Dis 2004,16(1),283-289","journal-title":"Neurobiol Dis"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1161\/HYPERTENSIONAHA.119.13133","volume":"74","author":"Mukerjee S.","year":"2019","unstructured":"Mukerjee S.; Gao H.; Xu J.; Sato R.; Zsombok A.; Lazartigues E.; ACE2 and ADAM17 interaction regulates the activity of presympathetic neurons. Hypertension 2019,74(5),1181-1191","journal-title":"Hypertension"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1097\/CM9.0000000000001106","volume":"134","author":"Jin S.","year":"2020","unstructured":"Jin S.; Dai J.; Teng X.; Wu Y.M.; Adverse effects of sympathetic activation should not be neglected during the coronavirus disease 2019 pandemic. Chin Med J (Engl) 2020,134(4),413-414","journal-title":"Chin Med J (Engl)"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1152\/jn.01329.2006","volume":"97","author":"Chen Q.","year":"2007","unstructured":"Chen Q.; Pan H.L.; Signaling mechanisms of angiotensin II-induced attenuation of GABAergic input to hypothalamic presympathetic neurons. J Neurophysiol 2007,97(5),3279-3287","journal-title":"J Neurophysiol"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/j.clinph.2021.03.001","volume":"132","author":"Versace V.","year":"2021","unstructured":"Versace V.; Sebastianelli L.; Ferrazzoli D.; Intracortical GABAergic dysfunction in patients with fatigue and dysexecutive syndrome after COVID-19. Clin Neurophysiol 2021,132(5),1138-1143","journal-title":"Clin Neurophysiol"},{"key":"ref=80","first-page":"2080409","volume":"101","year":"2010","unstructured":"Trailovi\u0107 SM, Nedeljkovi\u0107 JT. Central and peripheral neurotoxic effects of Ivermectin in rats. J Vet Med Sci 2010,101,2080409","journal-title":"J Vet Med Sci"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.1002\/jcp.30055","volume":"236","author":"Li N.","year":"2021","unstructured":"Li N.; Zhao L.; Zhan X.; Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol 2021,236(4),2959-2975","journal-title":"J Cell Physiol"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.4155\/fmc-2021-0022","volume":"13","author":"Li Y.","year":"2021","unstructured":"Li Y.; Yang J.; Zhang Y.; Meng Q.; Bender A.; Chen X.; Computational drug repositioning for ischemic stroke: Neuroprotective drug discovery. Future Med Chem 2021,13(15),1271-1283","journal-title":"Future Med Chem"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"173629","DOI":"10.1016\/j.ejphar.2020.173629","volume":"889","author":"Costa L.H.A.","year":"2020","unstructured":"Costa L.H.A.; Santos B.M.; Branco L.G.S.; Can selective serotonin reuptake inhibitors have a neuroprotective effect during COVID-19? Eur J Pharmacol 2020,889,173629","journal-title":"Eur J Pharmacol"},{"key":"ref=84","first-page":"12","volume":"2","author":"Adiraju R.K.","year":"2017","unstructured":"Adiraju R.K.; Dysautonomia: A novel approach to understanding of vasculitis and type Ii diabetes. J Rheumatol Arthritic Dis 2017,2(3),12","journal-title":"J Rheumatol Arthritic Dis"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-019-1251-7","volume":"38","author":"Jiang L.","year":"2019","unstructured":"Jiang L.; Wang P.; Sun Y.J.; Wu Y.J.; Ivermectin reverses the drug resistance in cancer cells through EGFR\/ERK\/Akt\/NF-\u03baB pathway. J Exp Clin Cancer Res 2019,38(1),1-8","journal-title":"J Exp Clin Cancer Res"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-021-00575-7","volume":"6","author":"Wu Y.","year":"2021","unstructured":"Wu Y.; Ma L.; Cai S.; Zhuang Z.; Zhao Z.; Jin S.; RNA-induced liquid phase separation of SARS-CoV-2 nucleocapsid protein facilitates NF-\u03baB hyper-activation and inflammation. Signal Transduct Target Ther 2021,6(1),1-3","journal-title":"Signal Transduct Target Ther"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.neuroscience.2014.03.039","volume":"269","author":"Zhao M.","year":"2014","unstructured":"Zhao M.; Zhou A.; Xu L.; Zhang X.; The role of TLR4-mediated PTEN\/PI3K\/AKT\/NF-\u03baB signaling pathway in neuroinflammation in hippocampal neurons. Neuroscience 2014,269,93-101","journal-title":"Neuroscience"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.molcel.2006.04.017","volume":"22","author":"Close P.","year":"2006","unstructured":"Close P.; Hawkes N.; Cornez I.; Transcription impairment and cell migration defects in elongator-depleted cells: Implication for familial dysautonomia. Mol Cell 2006,22(4),521-531","journal-title":"Mol Cell"},{"key":"ref=89","first-page":"3397","volume":"17","author":"Dominguez-Gomez G.","year":"2018","unstructured":"Dominguez-Gomez G.; Chavez-Blanco A.; Medina-Franco J.L.; Ivermectin as an inhibitor of cancer stem-like cells. Mol Med Rep 2018,17(2),3397-3403","journal-title":"Mol Med Rep"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"108516","DOI":"10.1016\/j.intimp.2021.108516","volume":"104","author":"Al-Kuraishy H.M.","year":"2022","unstructured":"Al-Kuraishy H.M.; Al-Gareeb A.I.; Al-Hussaniy H.A.; Al-Harcan N.A.H.; Alexiou A.; Batiha G.E.; Neutrophil Extracellular Traps (NETs) and Covid-19: A new frontiers for therapeutic modality. Int Immunopharmacol 2022,104,108516","journal-title":"Int Immunopharmacol"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"17590914211057635","DOI":"10.1177\/17590914211057635","volume":"13","author":"Al-Kuraishy H.M.","year":"2021","unstructured":"Al-Kuraishy H.M.; Al-Gareeb A.I.; Qusti S.; Alshammari E.M.; Gyebi G.A.; Batiha G.E.; Covid-19-induced dysautonomia: A menace of sympathetic storm. ASN Neuro 2021,13,17590914211057635","journal-title":"ASN Neuro"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"112193","DOI":"10.1016\/j.biopha.2021.112193","volume":"143","author":"Al-Kuraishy H.M.","year":"2021","unstructured":"Al-Kuraishy H.M.; Al-Gareeb A.I.; Qusti S.; Alshammari E.M.; Atanu F.O.; Batiha G.E.; Arginine vasopressin and pathophysiology of COVID-19: An innovative perspective. Biomed Pharmacother 2021,143,112193","journal-title":"Biomed Pharmacother"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.brainres.2014.06.018","volume":"1585","author":"Wei M.","year":"2014","unstructured":"Wei M.; Li H.; Shang Y.; Zhou Z.; Zhang J.; Increased CD147 (EMMPRIN) expression in the rat brain following traumatic brain injury. Brain Res 2014,1585,150-158","journal-title":"Brain Res"},{"key":"ref=94","first-page":"1","volume":"15","author":"Zaidi A.K.","year":"2021","unstructured":"Zaidi A.K.; Dehgani-Mobaraki P.; The mechanisms of action of ivermectin against SARS-CoV-2: An evidence-based clinical review article. J Antibiot (Tokyo) 2021,15,1-3","journal-title":"J Antibiot (Tokyo)"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1186\/s13071-021-04810-6","volume":"14","author":"Wilson N.E.","year":"2021","unstructured":"Wilson N.E.; Reaves B.J.; Wolstenholme A.J.; Lack of detectable short-term effects of a single dose of ivermectin on the human immune system. Parasit Vectors 2021,14(1),304","journal-title":"Parasit Vectors"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"808603","DOI":"10.22541\/au.162151000.01734906\/v1","volume":"14","author":"Deckmyn B.","year":"2021","unstructured":"Deckmyn B.; Domenger D.; Staels B.; Bantubungi K.; Farnesoid X.; Receptor activation in brain alters brown adipose tissue function via the sympathetic system. Authorea Preprints 2021,14,808603","journal-title":"Authorea Preprints"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1002\/hep.31712","volume":"74","author":"Ito K.","year":"2021","unstructured":"Ito K.; Okumura A.; Takeuchi J.S.; Dual agonist of farnesoid X receptor and takeda G protein-coupled receptor 5 inhibits hepatitis B virus infection in vitro and in vivo. Hepatology 2021,74(1),83-98","journal-title":"Hepatology"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1001\/jama.2021.3071","volume":"325","author":"L\u00f3pez-Medina E.","year":"2021","unstructured":"L\u00f3pez-Medina E.; L\u00f3pez P.; Hurtado I.C.; Effect of ivermectin on time to resolution of symptoms among adults with mild COVID-19: A randomized clinical trial. JAMA 2021,325(14),1426-1435","journal-title":"JAMA"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"266","DOI":"10.4103\/1995-7645.318304","volume":"14","author":"Niaee M.S.","year":"2021","unstructured":"Niaee M.S.; Namdar P.; Allami A.; Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: A randomized multi-center clinical trial. Asian Pac J Trop Med 2021,14(6),266","journal-title":"Asian Pac J Trop Med"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"102186","DOI":"10.1016\/j.dsx.2021.102186","volume":"15","author":"Zein A.F.M.Z.","year":"2021","unstructured":"Zein A.F.M.Z.; Sulistiyana C.S.; Raffaelo W.M.; Pranata R.; Pranata R.; Ivermectin and mortality in patients with COVID-19: A systematic review, meta-analysis, and meta-regression of randomized controlled trials. Diabetes Metab Syndr 2021,15(4),102186","journal-title":"Diabetes Metab Syndr"},{"key":"ref=101","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1136\/bmjebm-2021-111678","volume":"27","author":"Garegnani L.I.","year":"2022","unstructured":"Garegnani L.I.; Madrid E.; Meza N.; Misleading clinical evidence and systematic reviews on ivermectin for COVID-19. BMJ Evid Based Med 2022,27(3),156-158","journal-title":"BMJ Evid Based Med"},{"key":"ref=102","first-page":"CD015017","author":"Popp M.","year":"2021","unstructured":"Popp M.; Stegemann M.; Metzendorf M.I.; Ivermectin for preventing and treating COVID\u201019. Cochrane Database Syst Rev 2021(7),CD015017","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.chest.2020.10.009","volume":"159","author":"Rajter J.C.","year":"2021","unstructured":"Rajter J.C.; Sherman M.S.; Fatteh N.; Vogel F.; Sacks J.; Rajter J.J.; Use of ivermectin is associated with lower mortality in hospitalized patients with coronavirus disease 2019: The ivermectin in COVID nineteen study. Chest 2021,159(1),85-92","journal-title":"Chest"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3329\/jbcps.v38i0.47512","volume":"12","author":"Alam M.T.","year":"2020","unstructured":"Alam M.T.; Murshed R.; Bhiuyan E.; Saber S.; Alam R.F.; Robin R.C.; A case series of 100 COVID-19 positive patients treated with combination of ivermectin and doxycycline. J Bangladesh Coll Phys Surg 2020,12,10-15","journal-title":"J Bangladesh Coll Phys Surg"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"642822","DOI":"10.3389\/fphar.2021.642822","volume":"12","author":"Al-Kuraishy H.M.","year":"2021","unstructured":"Al-Kuraishy H.M.; Al-Gareeb A.I.; Alqarni M.; Cruz-Martins N.; El-Saber B.G.; Pleiotropic effects of tetracyclines in the management of COVID-19: Emerging perspectives. Front Pharmacol 2021,12,642822","journal-title":"Front Pharmacol"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"125","DOI":"10.3329\/jbcps.v38i0.47514","author":"Rahman M.A.","year":"2020","unstructured":"Rahman M.A.; Iqbal S.A.; Islam M.A.; Niaz M.K.; Hussain T.; Siddiquee T.H.; Comparison of viral clearance between Ivermectin with doxycycline and hydroxychloroquine with azithromycin in COVID-19 patients. J Bangladesh Coll Physicians Surg 2020,125-129","journal-title":"J Bangladesh Coll Physicians Surg"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10238-022-00836-x","author":"Al-Kuraishy H.M.","year":"2022","unstructured":"Al-Kuraishy H.M.; Al-Gareeb A.I.; El-Bouseary M.M.; Sonbol F.I.; Batiha G.E.; Hyperviscosity syndrome in COVID-19 and related vaccines: Exploring of uncertainties. Clin Exp Med 2022,1-10","journal-title":"Clin Exp Med"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"100915","DOI":"10.1016\/j.nmni.2021.100915","volume":"43","author":"Cadegiani F.A.","year":"2021","unstructured":"Cadegiani F.A.; Goren A.; Wambier C.G.; McCoy J.; Early COVID-19 therapy with azithromycin plus nitazoxanide, ivermectin or hydroxychloroquine in outpatient settings significantly improved COVID-19 outcomes compared to known outcomes in untreated patients. New Microbes New Infect 2021,43,100915","journal-title":"New Microbes New Infect"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"117271","DOI":"10.1016\/j.jns.2020.117271","volume":"420","author":"Ortelli P.","year":"2021","unstructured":"Ortelli P.; Ferrazzoli D.; Sebastianelli L.; Neuropsychological and neurophysiological correlates of fatigue in post-acute patients with neurological manifestations of COVID-19: Insights into a challenging symptom. J Neurol Sci 2021,420,117271","journal-title":"J Neurol Sci"}],"container-title":["Current Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389450123666220810102406","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/207352\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389450123666220810102406","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T14:07:08Z","timestamp":1700921228000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/207352\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":109,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389450123666220810102406","relation":{},"ISSN":["1389-4501"],"issn-type":[{"value":"1389-4501","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-12-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-17","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}